Patient population
Melanoma
BRAF GENE MUTATION, MELANOMA, NRAS GENE MUTATION
In this study, a total of 164 patients were selected and 119 patients were enrolled at 11 centers in China, of whom 42.9% were males and 57.1% were females. Their median age was 59 (23–74) years. ECOG PS in 42.9% of the patients were scored 0, and the rest were scored 1. The proportion of primary cutaneous subtype was 18.5%, acral subtype was 52.1%, mucosal subtype was 19.3%, and those with unknown primary site was 10.1%. Melanoma in 22.7% of the patients was stage III, and 72.9% were stage IV. Seven point six percent of the patients had NRAS gene mutation, and 10.9% had BRAF gene mutation. Patients received 1, 2, or ≥ 3 lines of previous treatments were 63.9%, 28.6%, and 7.6%, respectively. Baseline characteristics are listed in Table Summary of patient characteristics